Search clinical trials for: Resectable Adenocarcinoma of the Pancreas

Total 448509 results

Enrico De Toni

Recruiting

Sequential or Up-front Triple Treatment With Durvalumab, Tremelimumab and Bevacizumab for Non-resectable Hepatocellular Carcinoma (HCC) Patients (MONTBLANC)

Hepatocellular Carcinoma

Germany
Shanghai Zhongshan Hospital
Fudan University

Not yet recruiting

Neoadjuvant/Adjuvant Sintilimab, Nab-paclitaxel, and Gemcitabine for Resectable/Borderline Resectable Pancreatic Cancer

Pancreatic Cancer Stage III | Pancreatic Cancer, Stage IB | Pancreatic Cancer, Stage IIA | Pancreatic Cancer, Stage IIB

China
Academisch Medisch Centrum - Universiteit van Amsterdam...
M.D. Anderson Cancer Center; University of Colorado, Denver; Radboud University... and other collaborators

Recruiting

PREOPANC-4 Implementation Program for Locally Advanced Pancreatic Cancer (PREOPANC-4)

Pancreatic Cancer | Chemotherapy Effect | Locally Advanced Pancreatic Adenocarcinoma | Pancreatic Adenocarcinoma Non-resectable

Netherlands
Mayo Clinic
National Cancer Institute (NCI)

Recruiting

An Investigational Scan (68Ga-FAPI-46 PET/CT) for the Imaging of Cancer-Associated Fibroblasts in Patients With Localized Pancreatic Ductal Adenocarcinoma

Stage 0 Pancreatic Cancer AJCC v8 | Stage I Pancreatic Cancer AJCC v8 | Stage IIA Pancreatic Cancer AJCC v8 | Resectable Pancreatic Ductal Adenocarcinoma | Localized Pancreatic Adenocarcinoma

United States
Baylor College of Medicine
Merck Sharp & Dohme LLC; The Methodist Hospital Research Institute

Recruiting

Neoadjuvant Folfirinox Combined With Pembrolizumab Followed by Surgery for Patients With Resectable Pancreatic Cancer

Pancreatic Ductal Adenocarcinoma

United States
University Hospital, Lille
Ministry of Health, France

Recruiting

Efficacy and Safety of TPIAT for Resectable Adenocarcinoma of the Pancreas Region at High Risk of Postoperative Fistula (TPIAT-01)

Adenocarcinoma of the Pancreas | Ampullary Adenocarcinoma | Adenocarcinoma of the Duodenum

France
Erasme University Hospital
Jules Bordet Institute; University Hospital St Luc, Brussels; Belgian Group of...

Recruiting

Preoperative mFOLFIRINOX (or Gem-Nab-P) +/- Isotoxic High-dose SBRT for Borderline Resectable Pancreatic Adenocarcinoma (STEREOPAC)

Pancreatic Adenocarcinoma | Borderline Resectable Pancreatic Adenocarcinoma | Pancreatic Neoplasm

Belgium
GC Cell Corporation

Recruiting

Safety and Efficacy of Immuncell-LC With Gemcitabine in Resectable Pancreatic Cancer

Pancreatic Ductal Adenocarcinoma

Korea, Republic of
M.D. Anderson Cancer Center

Recruiting

Gemcitabine, Nab-paclitaxel, Durvalumab, and Oleclumab Before Surgery for the Treatment of in Resectable/Borderline Resectable Primary Pancreatic Cancer

Borderline Resectable Pancreatic Adenocarcinoma | Stage IA Pancreatic Cancer AJCC v8 | Stage IB Pancreatic Cancer AJCC v8 | Stage IIA Pancreatic Cancer AJCC v8 | Stage IIB Pancreatic Cancer AJCC v8 | Resectable Pancreatic Adenocarcinoma

United States
Erasmus Medical Center
Dutch Cancer Society; Dutch Pancreatic Cancer Group

Recruiting

Perioperative or Adjuvant mFOLFIRINOX for Resectable Pancreatic Cancer (PREOPANC-3)

Pancreatic Cancer | Pancreatic Ductal Adenocarcinoma | Resectable Pancreatic Adenocarcinoma

Netherlands, Sweden, Norway
West Virginia University

Recruiting

Neoadjuvant mFOLFIRINOX With Perioperative Oral Hydroxychloroquine in Resectable Pancreatic Adenocarcinoma

Adenocarcinoma of the Pancreas

United States
University Hospital Birmingham NHS Foundation Trust

Recruiting

The DISSECT Study: Effect of Peri-aDventItial SMA diSsECtion on Margin sTatus During Pancreaticoduodenectomy for Resectable Pancreatic Cancer

Pancreatic Adenocarcinoma

United Kingdom
National Cancer Institute (NCI)

Recruiting

APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation

Pancreatic Acinar Cell Carcinoma | Pancreatic Adenosquamous Carcinoma | Pancreatic Squamous Cell Carcinoma | Resectable Pancreatic Acinar Cell Carcinoma | Resectable Pancreatic Adenocarcinoma | Resectable Pancreatic Adenosquamous Carcinoma | Resectable Pancreatic Carcinoma

United States
Fudan University
West China Hospital; Tongji Hospital; Qilu Hospital of Shandong University; Zhejiang... and other collaborators

Recruiting

Laparoscopic Versus Open Pancreatoduodenectomy Following Neoadjuvant Chemotherapy for BRPC

Borderline Resectable Pancreatic Cancer

China
Fudan University

Recruiting

AG vs mFOLFIRINOX as Neoadjuvant Therapy for Borderline Reseactable and Locally Advanced Pancreatic Cancer

Locally Advanced Pancreatic Adenocarcinoma | Borderline Resectable Pancreatic Cancer

China
OHSU Knight Cancer Institute
Oregon Health and Science University

Recruiting

NeoOPTIMIZE: Early Switching of mFOLFIRINOX or Gemcitabine/Nab-Paclitaxel Before Surgery for the Treatment of Resectable, Borderline Resectable, or Locally-Advanced Unresectable Pancreatic Cancer

Pancreatic Adenocarcinoma | Stage III Pancreatic Cancer AJCC v8 | Stage IV Pancreatic Cancer AJCC v8 | Stage 0 Pancreatic Cancer AJCC v8 | Stage I Pancreatic Cancer AJCC v8

United States
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Recruiting

Testing the Use of the Usual Chemotherapy Before and After Surgery for Removable Pancreatic Cancer

Pancreatic Cancer | Pancreatic Adenosquamous Carcinoma | Resectable Pancreatic Adenocarcinoma

United States, Canada
University of Nebraska
National Cancer Institute (NCI)

Recruiting

FOLFIRINOX With Digoxin in Patients With Resectable Pancreatic Cancer

Pancreas Cancer | Adenocarcinoma of the Pancreas

United States
University of Utah
National Cancer Institute (NCI)

Recruiting

Losartan and Hypofractionated Rx After Chemo for Tx of Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer (SHAPER) (SHAPER)

Stage II Pancreatic Cancer AJCC v8 | Stage III Pancreatic Cancer AJCC v8 | Borderline Resectable Pancreatic Adenocarcinoma | Stage IIA Pancreatic Cancer AJCC v8 | Stage IIB Pancreatic Cancer AJCC v8 | Locally Advanced Unresectable Pancreatic Adenocarcinoma | Locally Advanced Pancreatic Ductal...

United States
CNAO National Center of Oncological Hadrontherapy
Foundation IRCCS San Matteo Hospital

Recruiting

Carbon Ions Radiation Therapy for Resectable or Borderline Resectable Pancreas Adenocarcinoma (PIOPPO)

Pancreas Adenocarcinoma | Resectable Pancreatic Cancer | Cancer of Pancreas

Italy
Second Affiliated Hospital, School of Medicine,...

Recruiting

Sequential Use of AG and mFOLFIRINOX as Neoadjuvant Chemotherapy for Resectable Pancreatic Cancer

Pancreatic Adenocarcinoma Resectable | Neoadjuvant Chemotherapy

China
Medical College of Wisconsin

Recruiting

Preoperative Fractionated Radiation Therapy Versus Stereotactic Body Radiation Therapy for Resectable or Borderline Resectable, or Locally Advanced Type A Pancreatic Adenocarcinoma

Pancreatic Cancer

United States
Loma Linda University

Recruiting

Testing the Combination of Two Approved Chemotherapy Drugs and Radiation Prior to Surgery in Localized Pancreatic Cancer

Pancreas Adenocarcinoma | Resectable Pancreatic Cancer

United States
Hospital General de Ciudad Real

Recruiting

Intrabdominal Hyperthermic Chemotherapy and Pancreatic Cancer

Resectable Pancreatic Adenocarcinoma

Spain
Sidney Kimmel Comprehensive Cancer Center at Johns...
Bristol-Myers Squibb; National Cancer Institute (NCI)

Recruiting

Platform Study of Neoadjuvant and Adjuvant Immunotherapy for Patients With Resectable Adenocarcinoma of the Pancreas

Pancreatic Cancer

United States
Silenseed Ltd

Recruiting

A Phase 2 Study of siG12D LODER in Combination With Chemotherapy in Patients With Locally Advanced Pancreatic Cancer (PROTACT)

Pancreatic Cancer | Pancreatic Ductal Adenocarcinoma

United States, Israel
Hospital del Mar

Completed

Prospective Registry of Patients With Pancreas Adenocarcinoma Resectable and Borderline (PaNLoCat)

Chemotherapy Effect | Pancreas Cancer

Spain
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

New and Emerging Therapies for the Treatment of Resectable, Borderline Resectable, or Locally Advanced Pancreatic Cancer, PIONEER-Panc Study

Borderline Resectable Pancreatic Adenocarcinoma | Resectable Pancreatic Ductal Adenocarcinoma | Locally Advanced Pancreatic Ductal Adenocarcinoma

United States
Jonsson Comprehensive Cancer Center
Bristol-Myers Squibb; NovoCure Ltd.

Active, not recruiting

Nivolumab in Combination With Chemotherapy Pre-Surgery in Treating Patients With Borderline Resectable Pancreatic Cancer

Borderline Resectable Pancreatic Adenocarcinoma | Resectable Pancreatic Ductal Adenocarcinoma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

NBTXR3 Activated by Radiation Therapy for the Treatment of Locally Advanced or Borderline-Resectable Pancreatic Cancer

Stage III Pancreatic Cancer AJCC v8 | Borderline Resectable Pancreatic Adenocarcinoma | Resectable Pancreatic Ductal Adenocarcinoma | Locally Advanced Pancreatic Ductal Adenocarcinoma

United States
Emory University
National Cancer Institute (NCI); National Institutes of Health (NIH); Vaccinex...

Completed

VX15/2503 and Immunotherapy in Resectable Pancreatic and Colorectal Cancer

Pancreatic Adenocarcinoma | Stage III Pancreatic Cancer | Colorectal Adenocarcinoma | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage II Pancreatic Cancer | Stage IV Colorectal Cancer | Stage IVA Colorectal Cancer | Stage IVB Colorectal Cancer | Stage I Pancreatic Cancer | Resectable Pancreatic... and other conditions

United States
Academic Thoracic Oncology Medical Investigators...
University of Colorado, Denver; Celgene Corporation; Criterium, Inc.

Active, not recruiting

Perioperative Therapy for Resectable and Borderline-Resectable Pancreatic Adenocarcinoma With Molecular Correlates

Pancreatic Cancer | Pancreatic Adenocarcinoma | Pancreas Ductal Adenocarcinoma

United States
Abramson Cancer Center at Penn Medicine

Completed

A Randomized Pilot/Pharmacodynamic/Genomic Study of Neoadjuvant Paricalcitol to Target the Microenvironment in Resectable Pancreatic Cancer

Adenocarcinoma of the Pancreas

United States
Jonsson Comprehensive Cancer Center
Arcus Biosciences, Inc.

Suspended

Zimberelimab and Quemliclustat in Combination With Chemotherapy for the Treatment of Patients With Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma

Borderline Resectable Pancreatic Adenocarcinoma | Locally Advanced Pancreatic Ductal Adenocarcinoma

United States
Sidney Kimmel Comprehensive Cancer Center at Johns...
Eli Lilly and Company; Merck Sharp & Dohme LLC

Completed

Pilot Study With CY, Pembrolizumab, GVAX, and IMC-CS4 (LY3022855) in Patients With Borderline Resectable Adenocarcinoma of the Pancreas

Pancreatic Cancer

United States
Albert Einstein College of Medicine
National Cancer Institute (NCI)

Terminated

Gemcitabine Hydrochloride, and Radiation Therapy in Patients With Borderline Resectable Pancreatic Cancer

Pancreatic Adenocarcinoma | Stage III Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer

United States
University of Florida
Ipsen

Active, not recruiting

A Study of the Safety and Activity of Liposomal Irinotecan in Combination With the 5-FU and Oxaliplatin in the Preoperative Treatment of Pancreatic Adenocarcinoma

Pancreatic Adenocarcinoma

United States
University Hospital Plymouth NHS Trust
University of Plymouth

Completed

Recurrence After Whipple's (RAW) Study

Pancreatic Cancer | Surgery | Bile Duct Cancer | Pancreatic Ductal Adenocarcinoma | Survivorship | Cholangiocarcinoma, Extrahepatic | Cancer Recurrence | Recurrent Cancer | Pancreatic Ductal Carcinoma | Cholangiocarcinoma of the Extrahepatic Bile Duct | Ampullary Cancer | Cholangiocarcinoma Resectable | Cancer... and other conditions

Spain, United Kingdom, Australia, Austria, Italy, Mexico, Sudan, Pakistan
University of Nebraska
National Cancer Institute (NCI)

Completed

Chemotherapy, Stereotactic Body Radiation Therapy & Nelfinavir Mesylate in Locally Advanced Pancreatic Cancer

Pancreatic Adenocarcinoma | Stage III Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage II Pancreatic Cancer | Stage I Pancreatic Cancer | Resectable Pancreatic Carcinoma | Stage IA Pancreatic Cancer | Stage IB Pancreatic Cancer

United States
Gangnam Severance Hospital

Completed

Intraoperative Radiation Therapy for Resectable Pancreatic Cancer

Resectable Pancreatic Adenocarcinoma

Korea, Republic of
OHSU Knight Cancer Institute
Oregon Health and Science University; Celgene Corporation

Completed

Nab-paclitaxel and Gemcitabine Hydrochloride Followed by Radiation Therapy Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery

Pancreatic Adenocarcinoma | Resectable Pancreatic Carcinoma

United States
University of Southern California
National Cancer Institute (NCI); Vasgene Therapeutics, Inc

Terminated

Recombinant EphB4-HSA Fusion Protein With Standard Chemotherapy Regimens in Treating Patients With Advanced or Metastatic Solid Tumors

Stage IIIA Non-Small Cell Lung Cancer | Stage IIIB Non-Small Cell Lung Cancer | Pancreatic Adenocarcinoma | Head and Neck Squamous Cell Carcinoma | Recurrent Non-Small Cell Lung Carcinoma | Stage IV Non-Small Cell Lung Cancer | Metastatic Pancreatic Adenocarcinoma | Stage III Pancreatic Cancer | Stage... and other conditions

United States
Fondazione Policlinico Universitario Campus Bio-Medico

Completed

Preoperative CA 19.9 Level Predicts Lymph Node Metastasis in Resectable Adenocarcinoma of the Head of the Pancreas. (ICALYRA)

Pancreas Cancer
Celgene

Completed

Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) (apact)

Digestive System Diseases | Neoplasms | Neoplasms by Site | Endocrine System Diseases | Digestive System Neoplasms | Endocrine Gland Neoplasms | Pancreatic Neoplasms | Pancreatic Diseases | Gemcitabine | Antimetabolites, Antineoplastic

United States, Korea, Republic of, Canada, France, Spain, Belgium, Austria, Czechia, Denmark, Italy, Hong Kong, Singapore, Taiwan, Germany, Hungary, Australia, United Kingdom, Portugal, Ireland, Finland, Netherlands
AIO-Studien-gGmbH
Celgene; ClinAssess GmbH

Completed

Neoadjuvant Plus Adjuvant or Only Adjuvant Nab- Paclitaxel Plus Gemcitabine for Resectable Pancreatic Cancer (NEONAX)

Resectable Pancreatic Cancer | Ductal Adenocarcinoma of the Pancreas

Germany
University of Oxford
National Institute for Health Research, United Kingdom; Imunon

Withdrawn

PanDox: Targeted Doxorubicin in Pancreatic Tumours (PanDox)

Pancreatic Cancer Metastatic | Pancreatic Ductal Adenocarcinoma | Pancreatic Cancer Stage IV | Pancreatic Cancer Non-resectable

United Kingdom
Yale University

Terminated

Neoadjuvant Modified FOLFIRINOX and Stereotactic Body Radiation Therapy in Borderline Resectable Pancreatic Adenocarcinoma

Pancreatic Cancer

United States
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

S1505: Combination Chemotherapy or Gemcitabine Hydrochloride and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery

Pancreatic Adenocarcinoma | Resectable Pancreatic Carcinoma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Nab-Paclitaxel, Capecitabine, and Radiation Therapy Following Induction Chemotherapy in Treating Patients With Locally Advanced Pancreatic Cancer

Pancreatic Adenocarcinoma | Stage III Pancreatic Cancer AJCC v6 and v7 | Locally Advanced Pancreatic Adenocarcinoma | Borderline Resectable Pancreatic Adenocarcinoma | Stage II Pancreatic Cancer AJCC v6 and v7 | Stage IIA Pancreatic Cancer AJCC v6 and v7 | Stage IIB Pancreatic Cancer AJCC v6 and...

United States
University of Rochester

Completed

Pilot Study of Short-Course Preoperative Stereotactic Body Radiation Therapy for Resectable Pancreatic Cancer

Adenocarcinoma | Pancreatic Cancer

United States

Search clinical trials for: Resectable Adenocarcinoma of the Pancreas

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Angola

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations